OncRef
Skip to newsletter content
|
mCRPCJanuary 2026
0:00 / 3:07
Metastatic Castration Resistant Prostate Cancer — Monthly Compass
Jan 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in metastatic castration resistant prostate cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
metastatic castration resistant prostate cancer updates
Key Highlights
Key Highlights
  • Key Clinical Development Updates
    • China’s CDE accepted Curium’s IND for 177Lu‑PSMA‑I&T in PSMA‑positive mCRPC, with an open‑label, randomized ~60‑patient Phase 3 bridging registrational study versus hormone therapy planned leveraging data from its ongoing global trial.
    • Alpha‑emitting PSMA RLT AB001 (212Pb‑PSMA) initiated dosing in the ARTISAN study with cohorts including both 177Lu‑PSMA–naïve and –experienced patients to inform sequencing in mCRPC.
  • Key Conference Updates
    • At the AACR Special Conference (January 20–22, 2026), early‑phase PDS01ADC (tumor‑targeting IL‑12 immunocytokine/ADC) plus docetaxel achieved a median PFS of 9.6 months with frequent PSA declines and tolerability marked by transient flu‑like symptoms in heavily pretreated mCRPC.
    • Extracellular vesicle proteome profiling from 177Lu‑PSMA‑617–treated patients was highlighted as a liquid biomarker strategy to monitor treatment biology and enable biomarker‑guided optimization of PSMA radioligand therapy.
  • Important Drug Publication Updates
    • A MAGNITUDE retrospective analysis showed that both FoundationOneCDx (tissue) and Resolution HRD (plasma) assays identified HRR‑positive mCRPC patients who derived comparable, clinically meaningful benefit from niraparib plus abiraterone acetate, validating plasma‑based testing as an alternative to tissue testing for selection.
  • Important Clinical Trial Publications
    • The Phase 3 CheckMate 7DX trial in ARPI‑pretreated, chemotherapy‑naïve mCRPC showed no improvement in radiographic progression‑free or overall survival with nivolumab plus docetaxel versus docetaxel alone, indicating no benefit in an unselected population.
    • A first‑in‑human study of the PSMA×CD3 bispecific JNJ‑80038114 reported limited antitumor activity with high cytokine release syndrome and anti‑drug antibody rates leading to early discontinuation, highlighting format and selection challenges for T‑cell engagers in mCRPC.
  • Emerging Themes & Macro-Trends
    • January 2026 signals prioritize alpha‑radioligand therapy differentiation, investment in predictive biomarkers, re‑engineering of bispecific formats or combinations, and integration of AI‑driven risk tools for trial matching and resource planning.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-01-01 and 2026-01-31 about metastatic castration resistant prostate cancer.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Curium announced that the China CDE accepted its Investigational New Drug (IND) application for 177Lu‑PSMA‑I&T to treat PSMA‑positive metastatic castration‑resistant prostate cancer; the IND is now under review. Curium detailed plans for an open‑label, randomized Phase 3 bridging registrational study (~60 patients) comparing 177Lu‑PSMA‑I&T versus hormone therapy in Chinese mCRPC, leveraging data from its ongoing global trial. ¹ (read more)
Publications Related to Approved Drugs
Phase 3
darolutamide
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS This post hoc analysis of the Phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer (nmCRPC) demonstrates that darolutamide plus androgen-deprivation therapy significantly improves metastasis-free survival and overall survival compared to placebo, regardless of prior local therapy (radical prostatectomy or radiotherapy). The study confirms that the clinical benefits and maintenance of quality of life associated with darolutamide are consistent across patients with or without a history of definitive local intervention, supporting its broad utility in the nmCRPC setting.
Phase 3
enzalutamide
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age A post hoc analysis of the Phase 3 EMBARK trial evaluates the efficacy of enzalutamide, with or without leuprolide, in patients with high-risk biochemically recurrent nonmetastatic castration-sensitive prostate cancer, stratified by age (<70 vs ≥70 years). The results indicate that enzalutamide-based regimens significantly improve metastasis-free survival compared to leuprolide alone in both age groups, and while older patients experienced a higher rate of adverse events, the safety profile remained manageable, validating the treatment's efficacy across age demographics.
New Publications Related to Drugs in Clinical Trial Development
Phase 3
Clinical Performance of Tissue- and Plasma-Based Diagnostic Assays in Identifying Homologous Recombination Repair Gene Alterations in Patients with Metastatic Castration-Resistant Prostate Cancer following Treatment with Niraparib with Abiraterone Acetate Plus Prednisone (Niraparib + AAP) This retrospective analysis from the Phase 3 MAGNITUDE study demonstrated the clinical utility of both FoundationOneCDx (tissue) and Resolution HRD (plasma) assays in identifying patients with homologous recombination repair (HRR) gene alterations. Results indicated that patients identified as HRR-positive by either assay derived comparable and clinically meaningful benefits from the combination of niraparib and abiraterone acetate, validating the use of plasma-based testing as a viable alternative to tissue testing for patient selection.
Phase 3
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial The Phase 3 CheckMate 7DX trial evaluated the efficacy of adding the immune checkpoint inhibitor nivolumab to docetaxel in patients with metastatic castration-resistant prostate cancer who were chemotherapy-naive but pretreated with androgen receptor pathway inhibitors. The study failed to meet its primary endpoints, showing no significant improvement in radiographic progression-free survival or overall survival compared to docetaxel alone, indicating that this combination does not offer a therapeutic advantage in this unselected patient population.
Conference
Major Conference Updates
Conference Information
  • AACR Special Conference in Cancer Research: Innovations in Prostate Cancer Research and Treatment; Boston, MA; January 20–22, 2026. Overall sentiment: mCRPC field is pushing beyond AR signaling with momentum in radiotherapeutics, immune-engaging biologics, and translational/AI tools to personalize care. (read more)
  • Theme 1: Radiotherapeutics Move to Alpha and Biomarker-Guided Optimization
    • Significance: PSMA-targeted RLT is expanding with alpha-emitting programs and biomarker efforts to stratify responders and manage resistance.
    • Mechanism insights / clinical impact: Alpha RLT AB001 (212Pb-PSMA small molecule) initiated dosing in ARTISAN, including 177Lu-PSMA–naïve and –experienced cohorts, reflecting an intent to overcome β-emitter resistance; EV proteome profiling from patients treated with 177Lu‑PSMA‑617 highlights liquid biomarker approaches to monitor treatment biology. (read more)
    • Patient populations affected: PSMA-positive mCRPC across post-ARPI/post-chemotherapy settings; cohorts explicitly include prior 177Lu-PSMA exposure to inform sequencing. (read more)
  • Theme 2: Immunocytokine/ADC + Chemotherapy Combinations Re-ignite Immunity
    • Significance: Combining cytotoxic backbones with immune-stimulatory payloads seeks deeper, durable responses in heavily pretreated mCRPC.
    • Mechanism insights / clinical impact: PDS01ADC (tumor-targeting IL‑12 immunocytokine/ADC recognizing DNA–histone epitopes) plus docetaxel showed median PFS 9.6 months and frequent PSA declines in early-phase data at the AACR prostate conference; tolerability featured transient flu-like symptoms consistent with IL‑12 biology. (read more)
    • Patient populations affected: Third-line mCRPC after ARPI and chemotherapy; potential fit where immune cold biology limits checkpoint efficacy. (read more)
  • Theme 3: Bispecific Antibodies Face Recalibration in Solid Tumors
    • Significance: T‑cell engagers remain attractive but require format engineering to balance efficacy with CRS/immunogenicity in mCRPC.
    • Mechanism insights / clinical impact: JNJ‑80038114 (PSMAxCD3) first‑in‑human study reported limited anti‑tumor activity (low PSA50/PR rates) with high CRS and ADA incidence, leading to early discontinuation—underscoring the need for affinity/format tuning and patient selection. (read more)
    • Patient populations affected: Heavily pretreated mCRPC; future directions likely to prioritize alternative targets/formats and combination backbones. (read more)
  • Theme 4: AI-Enabled Risk Stratification for Short-Horizon Decisioning
    • Significance: Visit-level mortality prediction can prioritize supportive care, trial allocation, and sequencing amid multiple novel options.
    • Mechanism insights / clinical impact: A longitudinal GRU model achieved strong discrimination and calibration for 180-day mortality using routine vitals/labs; operationalizes alerting windows that can guide palliative integration and trial eligibility. (read more)
    • Patient populations affected: Broad mCRPC clinic populations across lines, independent of target expression, enabling system-level triage. (read more)
  • Significance
    • Expected clinical or translational readouts: Ongoing ARTISAN dose-escalation updates; continued accrual for PDS01ADC/docetaxel with study completion targeted in 2026; deeper biomarker analyses for 177Lu‑PSMA‑617 cohorts. (read more)
    • Regulatory or policy implications: Near‑term catalysts are unlikely from these early studies; AI tools may influence institutional pathways rather than labeling. (read more)
    • Potential shifts in standard of care: If alpha PSMA agents demonstrate safety/efficacy post‑177Lu, sequencing could shift; immunocytokine + taxane strategies may offer salvage options where PARP/ARPI have failed. (read more)
    • Strategic implications: Prioritize alpha‑RLT differentiation, invest in predictive biomarkers (EV proteomics), and re‑engineer bispecific formats or pairings; integrate AI risk tools for trial matching and resource planning. (read more)
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in metastatic castration resistant prostate cancer updated from 2026-01-01 to 2026-01-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-1----1
Not Yet Recruiting21--1-4
Recruiting14127-4239
Available-------
Approved for Marketing-------
Active, Not Recruiting617-3-17
Completed-------
Total221514-8261
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
No phase 1 trials completing within the next three months.
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Abiraterone Acetate/Niraparib, Prednisone NCT05689021 ACTIVE_NOT_RECRUITING Phase 2 Study of CJNJ-67652000 (Niraparib/Abiraterone Acetate Fixed-Dose Combination) and Prednisone for Metastatic Castration-Resistant Prostate Cancer Associated With SPOP Mutation With or Without Homologous Recombination Deficiency 2026-03-31
Cabazitaxel, Abiraterone Acetate, Androgen deprivation therapy, Prednisone NCT03419234 ACTIVE_NOT_RECRUITING Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial 2026-04-01
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
olaparib, abiraterone acetate NCT03732820 ACTIVE_NOT_RECRUITING A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study) 2026-04-27
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Darolutamide (Nubeqa, BAY1841788) NCT05348876 RECRUITING A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) 2026-01-28
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.